The Department of Health and Human Services will establish a public-private consortium to increase U.S. production of essential medicines and active pharmaceutical ingredients, the White House announced today. The consortium will initially focus on 50-100 critical drugs from the Food and Drug Administration’s essential medicines list, and commit an initial $60 million to develop novel technologies to manufacture active ingredients domestically.   
 
President Biden in February directed federal agencies to review and recommend actions to address vulnerabilities in the supply chains for active pharmaceutical ingredients, essential minerals, semiconductors and large capacity batteries. The HHS actions are among the recommendations included in a new White House report based on those reviews, which also address supply vulnerabilities in those other sectors.

 

Related News Articles

Chairperson's File
Public
Most hospitals and health systems are the largest organizations in our communities, providing critical services needed by every one of our neighbors. We take…
Headline
The AHA May 16 urged the Department of Commerce to consider tariff exceptions for critical minerals and derivative products used for medical purposes. Critical…
Headline
The AHA May 14 urged the Senate Finance Committee to take steps to strengthen the supply chain for essential pharmaceutical and other medical products. In…
Headline
The U.S. and China reached a joint agreement to temporarily reduce tariffs for 90 days, the White House announced May 12. Both countries will lower tariffs by…
Headline
AHA today submitted comments to the Department of Commerce on its Section 232 national security investigation of pharmaceutical and pharmaceutical ingredients…
Headline
President Trump April 9 announced that reciprocal tariffs that went into effect after midnight for certain nations will be paused for 90 days, while tariffs…